Teriparatide Prevented Near Atypical Femur Fracture by Reducing Cortical Thickening in a Symptomatic Patient With Prolonged Use of Oral Bisphosphonate: A Case Report

Jaspinder Kaur, Luis Chavez, Issac Sachmechi, Paul Kim

Abstract


Long-term bisphosphonate (BP) treatment is associated with adverse event of atypical femur fracture (AFF) due to their long-lasting unique bone-seeking properties, and subsequent uptake by osteoclasts results in sustained inhibition of bone resorption even after their cessation. We report a case of postmenopausal women who presented with pain and severe femoral cortical thickening on alendronate for 10 years, but with no signs of obvious radiolucent fracture line on radiograph and bone marrow edema on magnetic resonance imaging representing impending AFF. Teriparatide (TPP) was started after discontinuation of BP which showed resolution of pain and reduction of femoral cortical thickness. We recommend biannual radiographs follow-up for evaluation of cortical thickening in patients taking BP along with the review of bone mineral density, and consideration of treatment with TPP if cortical thickening is present.




J Endocrinol Metab. 2016;6(6):183-186
doi: https://doi.org/10.14740/jem382w


Keywords


Atypical femur fracture; Bisphosphonate; Cortical thickening; Osteoporosis; Teriparatide

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!